جست‌وجوی استاد و پژوهشگر

Nicholas Fullerمشاهده پروفایل

دانشیار

• Obesity
• Weight Management
• Diabetes
• +۵ مورد دیگر

Associate Professor Nicholas Fuller is a prominent obesity researcher at The University of Sydney, serving as Clinical Trials Director within the Department of Endocrinology at Royal Prince Alfred Hospital and as a member of the Boden Initiative. His work bridges academic research and practical applications in weight management, with a focus on developing sustainable approaches to obesity treatment and prevention that consider the complex biological, psychological, and economic factors involved. Dr. Fuller's research interests center on preventing weight regain after dieting, a critical challenge in obesity management. He has developed the scientifically-proven Interval Weight Loss (IWL) program, which addresses the body's evolutionary resistance to sustained weight loss by incorporating strategic maintenance periods between weight loss phases. His work spans clinical trials, health economics, dietary interventions, and behavioral approaches to obesity treatment, with particular emphasis on translating research into real-world applications that improve population health. Analysis of his recent publications reveals a strong focus on evidence-based approaches to weight management, with significant contributions to understanding the effectiveness of dietary supplements, clinical assessment protocols for obesity, and economic factors influencing weight loss success. His research consistently appears in top medical journals including The Lancet, JAMA Network Open, and American Journal of Clinical Nutrition, with six of his top 10 publications ranking in the top 5% of all research outputs scored by Altmetric. Wentworth medal - The University of Sydney Accepted into the prestigious Incubate program - The University of Sydney Awarded the 'People's Choice Award' - Genesis, The University of Sydney University of Sydney Genesis Prize Awards from the Chancellor's Committee at the University of Sydney for research impact Dr. Fuller has secured significant funding for investigating diverse obesity interventions including dietary & exercise programs, complementary medicines, commercial weight loss programs, pharmaceutical drugs, medical devices, bariatric surgery, satiety hormones, and obesity economics. His work has resulted in policy changes in obesity management and has been featured in over 1,000 media appearances across television, radio, and print media. As a consultant for industry and government organizations, he provides expert guidance on obesity treatment approaches and has been ranked as the number 1 author on The Conversation in 2024. As Clinical Trials Director at the Charles Perkins Centre, Dr. Fuller leads research initiatives that combine cutting-edge technology with clinical expertise to develop innovative obesity treatments. His team provides comprehensive clinical analysis services from study design through to media dissemination, working with a broad portfolio of clients to evaluate emerging obesity treatments and technologies.

Rita Hartelمشاهده پروفایل

مدرس ارشد

• Data Compression
• Bioinformatics
• Graph Databases
• +۴ مورد دیگر

Dr. Rita Hartel serves as a Senior Lecturer and Research Associate in the Department of Databases and Electronic Commerce at the University of Paderborn's Institute of Computer Science, while also fulfilling the critical role of Academic Advisor for the Computer Science Student Office where she guides undergraduate and graduate students. Her research forms two distinct yet complementary pillars: cutting-edge data compression algorithms for bioinformatics (specializing in Burrows-Wheeler Transform optimizations for DNA sequence data) and graph databases (developing grammar-based compression for knowledge graphs), alongside innovative digital humanities work applying OCR and semantic analysis to comics historiography with a focus on German traditions. This interdisciplinary approach bridges computational rigor with cultural scholarship. Dr. Hartel demonstrates consistent research productivity with five publications from 2021-2025 in premier venues including the Data Compression Conference and specialized workshops. Her work reflects strong international collaboration patterns and likely benefits from active grant funding given the technical resources required for bioinformatics compression research. As an Academic Advisor, she provides essential student support while her dual research focus creates unique opportunities for students interested in either computational methods or digital humanities applications.

David S. Strayerمشاهده پروفایل

استاد

• Aids
• Bioterrorism
• Botulinum Toxin
• +۲۰ مورد دیگر

David S. Strayer is a Professor in the Department of Pathology & Genomic Medicine at Thomas Jefferson University's College of Life Sciences in Philadelphia, PA. His educational background: MD, University of Chicago, 1976 PhD, University of Chicago, 1976 Dr. Strayer's research focuses on the intersection of virology, molecular biology, and neurology. Key areas include HIV-associated neurocognitive disorders, gene therapy, and the molecular mechanisms of viral pathogenesis. His work has particular emphasis on: HIV and AIDS research Gene expression and regulation Neurocognitive disorders Virology (including poxviruses and SV40) Bioterrorism agents His recent publications highlight his focus on HIV-1-associated neurocognitive disorders, with studies on gene delivery of antioxidant enzymes and the assessment of neuronal loss. His work also extends to parasitic infections in immunocompromised patients and stem cell migration in the brain.

• Medical Pharmacology
• Toxicology
• Mushroom Toxins Research
• +۴ مورد دیگر

Prof. Dr. ERTUĞRUL KAYA is a Professor of Medical Pharmacology at Niğdge Ömer Halisdemir University Faculty of Medicine, having joined in 2023 after serving at Düzce University Faculty of Medicine from 2010-2023. His academic career progressed from Doctor Lecturer (2010-2014) to Associate Professor (2014-2020) and finally to Professor (2020-present). He has held significant administrative roles including Head of Department and Research Application Center Director. Education: Medical Specialization: Pamukkale University, Faculty of Medicine/Department of Internal Medical Sciences/Department of Medical Pharmacology (2002-2006) Thesis: Behavioral and biochemical effects of minocycline and nilvadipine in rats with cerebral ischemia induced by repeated four-vessel occlusion method Licence: Istanbul University, Istanbul Faculty of Medicine/Medicine Pr. (1992-1998) Prof. Kaya's research primarily focuses on toxicology, particularly mushroom toxins (amanitins, phallotoxins, grayanotoxins), pharmacological interventions for toxin-induced damage, and analytical methods for toxin detection. His work spans pharmacokinetics, hepatotoxicity, neurotoxicity, and the development of antidotes for mushroom poisoning. He has extensively studied Amanita species, Galerina marginata, and mad honey (grayanotoxin) toxicity, examining both the mechanisms of toxicity and potential therapeutic interventions using natural compounds and pharmaceutical agents. His 15 most recent publications demonstrate a strong emphasis on mycotoxicology, with particular focus on amatoxins, analytical methods for toxin detection, and therapeutic interventions. His research combines molecular biology, cell culture studies, animal models, and clinical case analyses to understand toxic mechanisms and develop countermeasures. A significant portion of his work addresses forensic applications of toxin analysis and the development of diagnostic tools for mushroom poisoning cases. Research Advising: Supervised 6 graduate students on topics including Amanita phalloides toxins, grayanotoxin effects, and antimicrobial properties of mushroom extracts Research projects span pharmacological effects of toxins, analytical methods, and potential therapeutic interventions Research Projects: Currently leading 2 ongoing projects related to regional honey analysis and experimental hypertension models Completed 25+ research projects primarily focused on mushroom toxins, amanitin pharmacokinetics, and analytical methods Secured funding from TÜBİTAK and university-supported research programs Prof. Kaya has developed patented diagnostic tools for mushroom poisoning, including an immunochromatographic card test for alpha-amanitin detection and gamma thiolactone derivatives for amanitin poisoning treatment. His work bridges laboratory research with clinical applications in toxicology and emergency medicine.

Mikkel Skovrindمشاهده پروفایل

پژوهشگر

• Molecular Ecology
• Evolutionary Biology
• Genomics
• +۵ مورد دیگر

Mikkel Skovrind is a Researcher at the University of Copenhagen's Globe Institute within the Section for Molecular Ecology and Evolution (Faculty of Health and Medical Sciences). He is actively conducting postdoctoral research focused on Arctic whales, particularly belugas, investigating their evolutionary and demographic histories across their circumpolar range. Skovrind describes himself as 'a classical naturalist driven by a fundamental curiosity' who employs cutting-edge genomic tools to address biological questions about genomic pattern formation. His research integrates genomic analyses with complementary data types including telemetrics, stable isotopes, and habitat modeling, believing that 'the inclusion of supporting data makes the impact of the genomic result much greater and helps put their implications in perspective.' His work spans molecular ecology, evolutionary biology, and population genetics with particular emphasis on Arctic marine ecosystems. His recent publications (2021-2024) reveal a strong research trajectory examining how environmental changes, especially climate fluctuations, have shaped evolutionary processes in diverse species. His methodological approach bridges traditional ecological techniques with modern genomic analyses, creating comprehensive insights into species adaptation and population dynamics. Skovrind earned his MSc in Biology with thesis work on 'Population structure of stenohaline anadromous fishes' on April 22, 2015. His scholarly impact is evident through Wikipedia references, news coverage, and significant social media engagement with his research outputs across platforms like X (formerly Twitter) and academic networks like Mendeley.

• Prostate Cancer
• Urologic Oncology
• Robotic Surgery
• +۷ مورد دیگر

Dr. Isaac Y. Kim, MD, PhD, MBA is Professor and Chair of the Department of Urology at Yale School of Medicine, Chief of Urology, and Co-Leader of the Cancer Signaling Networks Program at Yale Cancer Center. As a urologic oncologist and surgeon, he specializes in the treatment, management, and prevention of prostate cancer, with particular expertise in advanced and metastatic disease. Dr. Kim's research interests focus on two primary areas: the role of surgery in men with metastatic prostate cancer, and the mechanisms of treatment resistance in prostate cancer cells. His clinical work centers on minimally invasive robotic surgery, having performed over 2,500 robotic prostatectomies, with a focus on helping patients navigate and understand their disease. He has established a same-day radical prostatectomy program using single-port robotic surgery to minimize patient discomfort and recovery time. His research portfolio demonstrates consistent productivity across prostate cancer diagnostics, treatment, and outcomes. Recent publications address important topics including PSMA imaging, management of radio-recurrent prostate cancer, surgical outcomes in elderly patients, and novel approaches to treatment resistance. His work spans clinical trials, molecular research, and healthcare disparities in prostate cancer care. Dr. Kim leads the SIMCAP trial, a major multi-institution study evaluating cytoreductive prostatectomy in metastatic disease, and maintains active collaborations with numerous researchers across Yale and other institutions. His educational background includes medical and doctoral degrees from Northwestern University, a Wharton MBA, and clinical training at Baylor College of Medicine and NIH. As Chair of Urology, Dr. Kim oversees one of the larger urology departments in the nation, attracting patients from regions far beyond New Haven. He emphasizes delivering innovative care with compassion, noting that 'when a patient and concerned family members come in with a prostate cancer diagnosis, and I'm able to take care of it and see how he recovers, it is truly a privilege and a blessing.'

Charles Kuehnمشاهده پروفایل

دانشیار

• Astronomy
• Variable Stars
• Milky Way Formation
• +۱ مورد دیگر

Charles Kuehn serves as Associate Professor and Chair of the Physics & Astronomy department within the College of Natural and Health Sciences at the University of Northern Colorado. He has held this position since 2015, following postdoctoral appointments at the University of Sydney and Michigan State University. His academic credentials include: PhD in Astronomy and Astrophysics from Michigan State University (2011) MS in Astronomy and Astrophysics from Michigan State University (2008) BS in Astronomy from The Ohio State University (2005) Professor Kuehn's research spans observational astronomy with dual focus on variable stars (particularly RR Lyrae) and Milky Way formation . He investigates stellar populations in globular clusters and dwarf galaxies to reconstruct galactic assembly history. His complementary work in astronomy education research addresses pedagogical innovation in astronomy instruction, creating a unique bridge between astrophysical discovery and teaching methodology. Analysis of his 2006-2016 publications reveals consistent output in top astronomy journals, with concentration on variable star studies in the Large Magellanic Cloud and Milky Way halo. His work demonstrates increasing leadership in collaborative projects, with recent papers featuring international co-authors from Australia, Europe, and South America. As Department Chair and active researcher, Professor Kuehn oversees academic operations while maintaining research productivity. His role suggests supervision of graduate students and involvement in securing departmental funding, though specific grant details aren't provided. The absence of a named laboratory indicates research conducted through collaborative networks rather than a dedicated facility, providing students with opportunities in data analysis and international astronomical projects.

Philipp Unberathمشاهده پروفایل

استاد

• Artificial Intelligence in Healthcare
• Biomedical Informatics
• Cancer Genomics
• +۴ مورد دیگر

Philipp Unberath serves as Professor of Psychology at SRH University since 2022, holding a habilitation in psychology from Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) awarded in 2023. His career bridges clinical psychology practice and biomedical informatics innovation, with prior roles including 18 years as Research Assistant at FAU (2004-2022) focusing on legal psychology and developmental disorders. His research integrates artificial intelligence with healthcare through two complementary threads: Biomedical Informatics: Leading technical development of cancer genomics platforms (cBioPortal extensions, molecular tumor board systems, clinical decision support tools) Clinical Psychology: Specializing in developmental/abnormal psychology, legal psychology, and prevention programs for children/families This dual expertise enables human-centered design of healthcare IT systems that address both technical and psychological dimensions of patient care. Analysis of his 15 most recent publications (2019-2023) reveals a strategic pivot toward precision oncology informatics, with 80% of recent work focused on genomic data integration, molecular tumor boards, and clinical decision support systems. His psychological background informs usability studies and workflow implementations, creating a distinctive niche at the AI-healthcare-psychology intersection. Scientific recognition includes: Bavarian doctoral scholarship (2002-2004) Continuous high-impact publication in biomedical informatics (JMIR, Cancers, BMC Med Inform) As an active principal investigator, Prof. Unberath directs grant-funded projects developing clinical-genomic integration platforms. His supervision approach combines technical mentorship in health informatics with clinical psychology perspectives, preparing students for interdisciplinary healthcare innovation roles. Current work focuses on real-world implementation of AI-driven decision support in oncology settings.

Arie S. Belldegrunمشاهده پروفایل

استاد

• Urologic Oncology
• Kidney Cancer
• Prostate Cancer
• +۴ مورد دیگر

Dr. Arie S. Belldegrun is a Professor and Chief of the Department of Urology at the David Geffen School of Medicine at UCLA, holding the Roy and Carol Dumani Chair in Urology. He serves as Surgical Director of the Genitourinary Oncology program and Director of the Institute of Urology Oncology at UCLA. As a member of the Tumor Immunology & Immunotherapy program, Dr. Belldegrun maintains clinical appointments at both Ronald Reagan UCLA Medical Center in Los Angeles and UCLA Santa Monica Medical Center. MD, Hebrew University Hadassah Medical School, 1974 Surgical Oncology Fellowship, National Institutes of Health, 1985-1988 Research Fellowship, Weizmann Institute of Science, 1976-1979 Urology Residency, Brigham and Women's Hospital, 1982-1985 Dr. Belldegrun's research focuses on targeted specific therapy and immunotherapy of kidney and prostate cancers. His laboratory reported on the cloning of a tissue specific and androgen responsive novel 620 bp PSA promoter sequence, providing the foundation for developing tissue specific vectors for prostate cancer gene therapy. He has also studied the feasibility of isolating functional dendritic cells from renal cell carcinoma patients and compared their transduction efficiency using various gene transfer methods. His clinical interests span a broad range of urologic conditions including kidney cancer, prostate cancer, bladder cancer, and numerous other urologic malignancies and conditions. Analysis of Dr. Belldegrun's recent publications reveals a strong emphasis on renal cell carcinoma research, particularly in genomic characterization, biomarker development (especially carbonic anhydrase-IX), and immunotherapy approaches. His work spans clinical trials, genomic analysis, and translational research bridging laboratory findings to clinical applications. The research demonstrates consistent focus on improving diagnosis, prognosis, and treatment of urologic cancers, with particular attention to personalized medicine approaches. Top Doctors, Los Angeles Magazine, 2018 Dr. Belldegrun has been instrumental in developing clinical trial protocols for kidney cancer treatment, including the high-dose aldesleukin "select" trial for metastatic renal cell carcinoma. His research has secured substantial grant funding supporting translational work in immunotherapy and targeted therapy. His laboratory investigations into dendritic cell-based immunotherapy have contributed significantly to understanding immune responses in renal cell carcinoma. Dr. Belldegrun leads the Institute of Urology Oncology at UCLA, which integrates clinical care, research, and education in urologic malignancies. The institute focuses on developing innovative treatment approaches for kidney, prostate, and bladder cancers, with particular emphasis on immunotherapy and precision medicine strategies. Under his direction, the institute has established comprehensive clinical trials programs and translational research initiatives bridging laboratory discoveries with patient care.

• Space Biology
• Microgravity Research
• Neurobiology
• +۵ مورد دیگر

Marcel Egli serves as Head of the Institute for Medical Technology (IMT) at the Lucerne University of Applied Sciences and Arts (HSLU) within the School of Engineering & Architecture. His institute combines the Center of Competence in Bioscience and Medical Engineering, the Space Biology Group, and the User Support and Operational Center BIOTESC that serves the European Space Agency (ESA). The IMT offers study programs and complementary post-graduate courses in medical technology. Dr. Egli's research focuses on cellular mechanisms of mechanosensation induced by mechanical unloading (weightlessness). His academic journey began with training as a precision mechanic, followed by a master's degree in zoology from the University of Berne and multidisciplinary graduate studies in medicine and biology. He conducted postdoctoral research at the University of Melbourne and Florida State University, where he became Associate Faculty studying secretory rhythms of hormones in mammals. His appointment to lead the Space Biology Group at ETH Zurich brought him back to Switzerland, where he received his Venia Legendi in space biology before moving his research group to Lucerne to establish the Institute of Medical Engineering. Egli's publication record demonstrates a clear trajectory from neurobiology and neuro-endocrinology toward space biology research. His recent work utilizes diverse research platforms including parabolic flight maneuvers, sounding rockets, and International Space Station laboratories to investigate cellular responses to microgravity. His research spans cellular mechanosensation, calcium signaling, tissue engineering, and the development of space-compatible biomedical instrumentation. Dr. Egli has led numerous significant projects including Space Bioreactor development, COSMOS Data Cockpit for Personalized Medicine, research on astronauts' low back pain, and the CaSiPaC project studying calcium signaling during parabolic flight in chondrocytes. His work has received support from space agencies including ESA and the Canadian Space Agency. The Institute for Medical Technology under Egli's leadership operates as a multidisciplinary hub connecting space research with terrestrial medical applications. His team develops technologies that function in both space environments and Earth-based clinical settings, with particular emphasis on understanding how mechanical unloading affects biological systems at the cellular level. This research has implications for both space medicine and understanding terrestrial conditions like osteoporosis and muscle atrophy.